Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging data in ...

An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

A University of Minnesota Medical School-led research team has discovered that a cancer signaling pathway has previously unrecognized roles in retina and brain blood vessels. The findings were ...

A new wave of scientific understanding is placing ferroptosis, a distinct form of iron-dependent cell death, at the forefront ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

ASCO 2026 cancer breakthroughs from Chicago include daraxonrasib nearly doubling survival in metastatic pancreatic cancer, ...

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% ...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive ...